Boehringer Ingelheim

In 2004, Evotec entered into a multi-year drug discovery collaboration with Boehringer Ingelheim to jointly identify and develop preclinical development candidates for the treatment of various diseases. The agreement has been expanded and extended on two occasions since its initiation. Under the terms of the agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialization of the compounds identified. In return, Evotec receives ongoing research payments, preclinical milestones. Furthermore, the contract provides a substantial long-term benefit for Evotec through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market.

To date 15 milestones have been achieved as part of this agreement

18 August 2011
Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received

31 May 2011
Evotec receives Milestone as Boehringer Ingelheim starts Phase I clinical trial in Pain

19 May 2010
Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim